Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China

Xue et al., J. Med. Virology, June 17, 2020, doi:10.1002/jmv.26193
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
30 hospitalized patients. Early use of HCQ is more effective, 43% reduction in progression from moderate to severe. "Early" is relative here, within 7 days of hospitalization.
Xue et al., 17 Jun 2020, peer-reviewed, 7 authors.
This PaperHCQAll
Hydroxychloroquine treatment in COVID‐19: A descriptive observational analysis of 30 cases from a single center in Wuhan, China
Huiying Xue, Yi Liu, Pan Luo, Xiulan Liu, Lin Qiu, Dong Liu, Juan Li
Journal of Medical Virology, doi:10.1002/jmv.26193
Hydroxychloroquine (HCQ) garnered scientific attention in early February following publication of reports showing in vitro activity of chloroquine (CQ) against COVID-19. While studies are mixed on this topic, the therapeutic effect of HCQ or CQ still need more valid clinical evidence. In this descriptive observational study, we aimed to discuss the treatment response of HCQ in COVID-19 infected patients and 30 cases were included. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and interleukin-6 (IL-6) before and after HCQ therapy and clinical outcome in the 30 COVID-19 patients were assessed. In order to evaluate the effect of mediation time point, we also divided these cases into two groups, patients began administrated with HCQ within 7 days hospital (defined as early delivery group) and 7 days after hospital (defined as later delivery group). We found that, the elevated IL-6, a risk factor in severe patients were reduced to normal level after HCQ treatment. More importantly, patients treated with HCQ at the time of early hospital recovered faster than those who treated later or taken as second line choose for their obvious shorter hospitalization time. In summary, early use of HCQ was better than later use and the effect of IL-6 and CRP level can not be ruled out.
Accepted Article Discussion COVID-19, the novel coronavirus also named SARS-CoV-2, shares about 80% of the genetic sequence with SARS-CoV 7, 8 . Additionally, COVID-19 shares the same cell entry receptor, ACE2, with SARS-CoV 9 . HCQ and CQ inhibit receptor binding and membrane fusion, two key steps that are required for cell entry by coronaviruses. CQ has been shown to exert an antiviral effect during preand post-infection conditions by interfering with the glycosylation of angiotensinconverting enzyme 2 (ACE2) (the cellular receptor of SARS-CoV) and blocking virus fusion with the host cell 6, 10 . On March 31st, medRxiv.org published data of the first completed randomized clinical trial in Wuhan investigating the efficacy of HCQ in patients with COVID-19. The clinical research included 62 patients, and reported significant difference in time to clinical recovery (TTCR) and radiologic findings between the groups. Despite this, the evidence regarding its effect remains limited 11 . A retrospective analysis of 1061 cases reported that administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients 12 . However, another retrospective study of 1317 cases reported that no significant difference was found in terms of rates of usage of HCQ or CQ between those who were found positive for SARS-CoV-2 and those who were found negative 13 . On the whole, the exact effect is highly controversial...
References
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Cortegiani, Ingoglia, Ippolito, Giarratano, Einav, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care
Gendelman, Amital, Bragazzi, Watad, Chodick, Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis, Autoimmun Rev
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Million, Lagier, Gautret, Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis
Van Den Borne, Be, Dijkmans, De Rooij, Le Cessie et al., Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferongamma production by peripheral blood mononuclear cells, J Rheumatol
Vincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Xu, Chen, Wang, Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, Sci China Life Sci
Xu, Shi, Wang, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med
Zhang, Zhao, Zhang, The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China, Clin Immunol
Zhang, Zheng, Liu, Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, Liver Int
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemoth
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit